Company Overview of InteKrin Therapeutics Inc.
InteKrin Therapeutics Inc., a biopharmaceutical company, develops and commercializes therapeutics for inflammatory and metabolic disorders. The company offers INT131, a peroxisome proliferator-activated receptor gamma modulator that targets inflammation and activates neuroprotective pathways. The company was founded in 2005 and is based in Redwood City, California. As of February 12, 2014, InteKrin Therapeutics Inc. operates as a subsidiary of Coherus Biosciences, Inc.
201 Redwood Shores Parkway
Redwood City, CA 94065
Founded in 2005
Key Executives for InteKrin Therapeutics Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact InteKrin Therapeutics Inc., please visit www.intekrin.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.